

Index

- acquired immune deficiency syndrome (AIDS) 175–76, 186, 189–90, 192, 194
- ACS, *see* acute coronary syndrome
- active pharmaceutical ingredient (API) 181–82
- acute coronary syndrome (ACS) 40, 53, 57
- acute myeloid leukaemia (AML) 94–97, 102, 104
- adhesion 181, 208, 234, 244, 275, 295
- AFM, *see* atomic force microscopy
- AIDS, *see* acquired immune deficiency syndrome
- airway inflammation 328
- allergy 334–35
- allografts 195, 203, 207, 237
- alumina 121, 208–9, 320
- alveolar bone 260, 264–65, 267–70, 276
- ameloblasts 256, 261, 263, 265, 268–69, 271
- AML, *see* acute myeloid leukaemia
- antibodies 46, 49–50, 74, 103, 192, 295–96, 323
- antigen presenting cells (APC) 292, 298, 324
- antigens 17, 25, 180, 183, 185, 296, 298, 324, 327, 329–30, 333, 335
- pDNA-encoded 180, 183–86
- antioxidants 163–64, 294, 297
- antiretroviral drugs (ARVs) 175–76, 178, 188
- APC, *see* antigen presenting cells
- API, *see* active pharmaceutical ingredient
- apoptosis 42, 104–5, 107, 291, 294, 296, 299–301, 303–5, 307, 309
- aptamers 13–14
- arterial wall 42, 52
- arthritis 115–16, 118, 150, 207, 320
- articulating surfaces 318–19
- ARVs, *see* antiretroviral drugs
- aseptic loosening 322
- atherogenesis 41–42, 45
- atherosclerosis 39–41, 43–45, 47, 49, 51–53, 56–57, 295
- accurate diagnosis 44–45, 47, 49
- human 47, 49
- treatment 51, 53, 55, 57
- understanding of 41, 43
- atherosclerotic lesions 42–43, 50, 52, 57
- atherosclerotic plaques 42, 47, 49, 52
- atomic force microscopy (AFM) 13, 15–16, 72, 117, 234
- autografts 107, 195, 207, 237
- autoimmune diseases 23, 25
- bacteria 17, 180, 321, 323, 331, 335, 338
- bare metal stents (BMS) 53, 57
- BBB, *see* blood brain barrier
- biocompatibility 4, 72, 103, 147–48, 165, 196, 213, 230–32, 234, 237, 246, 291, 295
- biocompatible polymers 54, 230–31, 235–36, 241, 246

- biodegradable nanoparticles 52, 274, 317
- biosensors, label-free protein 13–14
- birth defects 162, 166–68
- blood brain barrier (BBB) 24, 26, 105
- blood cells 6, 206
 - white 98, 231, 325, 328
- blood diseases 93–94, 96, 98, 100, 102, 104, 106, 108, 110
- BMS, *see* bare metal stents
- bone 11, 115–16, 118–23, 195–96, 202, 206–9, 215, 257–59, 275, 305, 318, 322, 325–26
 - bone cells 120, 272–73, 322
 - bone remodelling 207–8
 - bone tissue 108, 120, 205, 208
 - natural 120
- bovine serum albumin (BSA) 233–34
- breast cancer 16, 75
- BSA, *see* bovine serum albumin
- calcium deposition 209–10
- cancer 4, 12, 17, 19–20, 23–24, 67–68, 71, 73, 76, 79, 97, 100, 102–3, 105, 245
 - treatment of 69, 71, 78, 97, 99, 102, 109, 118, 188, 293, 297, 317
- cancer cells 20, 24, 28, 71, 74, 76, 98, 101, 244
- cancer diagnostics 69–70, 73, 75, 100
- cancer research 68, 71, 78, 80
- cancer therapeutics 75–76
- cancer therapy 23, 71, 75–77, 164, 289, 294, 297, 310
- cancerous cells 101
- carbon black 327–28, 330–32, 335–36
- carbon nanotubes 6, 8, 274, 303, 332, 334–35
 - multi-walled 334
- cartilage 122, 195, 202, 207, 210–11, 256–57, 272–73
- cartilage regeneration 11, 211
- cationic lipids 139
- cell adhesion 12, 54, 121, 197, 209, 237, 244–45, 275
- cells
 - antigen-presenting 333
 - biological 229, 232
 - cycling 262
 - dental mesenchymal 256
 - human dental follicle 269
 - inflammatory 25, 42–43, 294, 298
 - mammalian 163, 165, 293
 - smooth muscle 42–43, 58, 212, 246, 258
 - syncytiotrophoblastic 149, 167
 - transplanted 268–69
- cellular membranes 3, 28, 148–49, 165
- cementum 259–60, 264, 267, 270
- central neural system (CNS) 25–26, 163, 168, 295
- ceramics 121, 202, 208–9, 218
- cerium oxide nanoparticles 163–64, 297
- cervical loop 261, 263
- chemotherapy 68, 93–94, 99, 105, 150
- chitosan 24–25, 178, 197, 200
- chronic myeloid leukaemia (CML) 97–98, 107
- circular dichroism 232–33, 257–60
- CMC, *see* critical micellar concentration
- CML, *see* chronic myeloid leukaemia

- CNS, *see* central neural system
- collagen 54, 197, 200–1, 205–6, 209–11, 213–14, 269, 275–76
- comet assay 305–9
- computed tomography (CT) 18, 46, 57–58
- critical micellar concentration (CMC) 134
- CT, *see* computed tomography
- curcumin 104
- cytokine secretion 299, 325–26, 329, 334
- cytokines 104, 296, 300, 325–26, 328–29, 334, 337
- cytotoxic T-cells 186, 323–24
- cytotoxicity 4, 273–74, 293, 296, 298–303, 308
- daunorubicin 78, 106
- DCs, *see* dendritic cells
- dendrimers 6, 8, 24–25, 47, 50, 166–67, 179
- dendritic cells 181, 193
- dendritic cells (DCs) 25, 175, 181–83, 185–86, 192–94, 296, 298, 300, 323–24, 328–31, 333, 336
- dendritic cells, activation of 329, 331
- dental follicle 257, 259–60
- dental mesenchymal stem cells (DMSCs) 257, 259, 269
- dental pulp 257, 259, 264–66, 269
- dental pulp cells 268
- dental pulp stem cells (DPSCs) 257–60, 263, 266–67, 269
- dental stem cells 256–57, 259, 261, 263
- dentin 256, 259, 267, 270
- DEP, *see* diesel exhaust particles
- DermaVir 181–86, 192, 194
- DermaVir immunisations, repeated 186–88
- developmental toxicity 163, 165
- diesel exhaust particles (DEP) 326–32, 335–36
- differential scanning calorimetry (DSC) 234–35
- disability 115–16
- diseases
- cardiovascular 12, 19, 39
 - early diagnosis of 12–13, 15, 17, 19
 - infectious 23, 25, 118, 192
 - joint 115–17
- DMSCs, *see* dental mesenchymal stem cells
- DNA 13–14, 17–19, 132, 134, 136, 186, 272, 274, 309–10
- DNA damage 165, 304–5, 307–9
- DNA nanoparticles 132, 135
- doxorubicin 22, 24, 78–79
- DPSCs, *see* dental pulp stem cells
- drug delivery 3, 5, 21, 27, 29, 52, 100, 105, 130, 177, 190, 241, 244, 293–94, 297
- drug delivery systems, nanocarrier-based 21, 24
- drugs, nanoparticle 100
- DSC, *see* differential scanning calorimetry
- ECM, *see* extracellular matrix
- ECs, *see* endothelial cells
- electrospinning 122, 199–200, 211, 213–14
- embryology 147–48, 150, 152, 154, 156, 158, 160–66, 168
- embryonic stem cells 264
- enamel 261, 263, 268, 270–71
- enamel organ 255
- enamel regeneration 263, 268, 270

- endothelial cells (ECs) 27, 42, 45, 49–50, 57, 74, 244–46, 267, 295
- endothelial cells, function of 42
- endothelium 41–43, 45, 53–54, 295
- endotoxin 323, 325, 329, 331–32, 337
- engineered nanomaterials 28, 161, 167, 310
- diversity of 161
- engineered nanoparticles 165
- eosinophilic granulocytes 323–24, 329–30
- epithelial cells 7, 179, 257, 263, 290, 332
- epithelial stem cells 261, 263, 269
- epithelium, inner enamel 255, 261–63
- ERM cells 263, 268
- extracellular matrix (ECM) 11, 42–44, 57, 120, 197, 199–201, 203, 206, 209, 211–12, 214, 218, 237, 275–76
- fibronectin 54–55, 215, 217, 274–75
- fluorescence 46, 48
- fullerenes 6, 8–9
- gemini nanoparticles 132–33, 135–37
- gemini surfactants 133–38
- genes 5, 12, 23–24, 71, 75, 93, 98, 163, 213, 271, 273, 307–8
- genotoxic effects 161, 305–7, 309–10
- long-term 306
- genotoxicity 289–92, 294, 296, 298, 300, 302, 304–6, 308, 310
- GFP, *see* green fluorescence protein
- gold 28, 69–71, 73, 75, 77–78, 102, 164, 332
- gold nanoparticles 18–19, 23–24, 47, 70, 72–74, 76–77, 165–66, 297–99, 307, 332–33
- green fluorescence protein (GFP) 272–73
- haematological cancers 103, 105, 107, 110
- haematological diseases 102, 110
- haematological malignancies 93, 100, 104, 109–10
- haematology 97, 99, 101–2, 109
- heat shock proteins (HSPs) 156
- high molecular weight polyethylene (HMWPE) 320
- HIV 175–76, 179–80, 188–89, 192–93
- HIV-infected cells 185
- HIV-infected individuals 187–88
- HIV proteins 182
- HMWPE, *see* high molecular weight polyethylene
- honeycomb films 239–45
- HSPs, *see* heat shock proteins
- human cells 6, 28, 269, 291, 309
- human health 2, 4, 28, 30, 148, 165, 290, 297, 310, 327
- human teeth 256, 261, 263, 267
- hydrogels 11, 24, 77–78, 198
- hydroxyapatite 120–21, 206, 208
- hyperthermia 79, 101–2
- imatinib 98, 107, 109
- immune cells 43, 175, 290–91, 293–94, 310, 332, 337–38
- immune system 42, 45, 176, 179–80, 290–92, 294, 299–300, 302, 318, 324–25, 327–29, 332, 334, 336, 338

- immunogenicity 7, 56, 180–82, 186–87, 194
- immunotherapeutic
 - nanomedicines 179, 181
- implants 12, 55, 119, 121, 123, 199, 208, 265, 268, 272, 319–22, 326
- induction, micronuclei 305–6
- infection 25, 176, 179, 207, 264, 266, 268, 301, 310, 318, 321–22, 331
- inflammation 44, 47, 55, 164, 207, 291–92, 294, 297, 299, 303, 318, 322, 324, 326, 328–29
- inflammatory responses 103, 197, 297, 300, 302, 306, 309, 325
- injury 117, 121, 256, 263–65, 273
- iron oxide 47, 69–71, 73, 75, 77–78, 317, 332–33
- iron oxide nanoparticles 71, 74–76, 294–96, 304, 333
- Iron oxide nanoparticles, small superparamagnetic 46, 48
- joint arthroplasty 118, 318, 321
- joint replacements 118–19, 208, 318
- L-lactic acid 182, 198, 203
- lab-on-a-chip 17–18
- laminin 55, 197, 214–15, 275
- Langerhans cells 182, 185, 193, 334
- late stent thrombosis 53–54
- LDL, *see* low density lipoprotein
- leukaemia
 - acute 94, 97, 106–7
 - acute lymphoblastic 94, 96–97
 - acute myeloid 96–97, 102, 104
- leukaemic cells 106–7
- liposomes 1, 6–7, 24–27, 46–47, 52, 69, 108, 179, 191
- low density lipoprotein (LDL) 42, 46, 57
- lung epithelial cells 291–92
- lungs 45, 148, 290–92, 294, 301–2, 330–31, 335
- lymph nodes 177, 185–86, 192, 292, 318, 323–24
- lymphocytes 74, 291, 293–94, 296, 299, 326, 331, 334
- lymphoma cells 99, 293
- macrophage functions 295, 325, 328–29, 337
- macrophage inflammatory protein (MIP) 300
- macrophage polarization 336
- macrophages 7, 22, 42–48, 51, 72, 175, 179, 290, 294–96, 298, 300, 322–26, 328–31, 333–34, 336–37
- magnetic nanoparticles 18, 20–21, 49, 71, 106, 272
 - applications 21
- magnetic resonance imaging (MRI) 18, 20–21, 46, 48–49, 57, 72, 78–79, 102, 272, 294, 296, 317
- mantle cell lymphoma (MCL) 103–4
- maternal organism 149, 166–68
- MCL, *see* mantle cell lymphoma
- MCP, *see* monocyte chemotactic protein
- MDR, *see* multi-drug resistance
- medical devices 229–30, 318
- medical nanoparticles 332–33, 335, 337
- mesenchymal stem cells (MSCs) 11, 122, 256–57, 260–61, 263, 268–69

- metallic nanoparticles 6, 302–3
 2-methoxyethyl acrylate 231
 micelles 6, 8, 25, 27, 47
 polymeric 8, 24
 microarrays 13, 16
 microenvironment 18, 200, 273,
 275
MIP, *see* macrophage inflammatory
 protein
 monocyte chemotactic protein
 (MCP) 297, 300
 monocytes 49, 206, 293–95, 325,
 334
MRI, *see* magnetic resonance
 imaging
 MSCs, *see* mesenchymal stem cells
 mucosal surfaces 25
 multi-drug resistance (MDR) 93,
 100, 106–7
 multipotent stem cells 258
 myeloma, multiple 108
- nanoarrays 16
 nanobiomaterials 118–20, 214
 nanocarriers 1, 5–7, 21–24,
 26–29, 78, 101
 nanoceria 163–64, 306–7
 nanoconjugates 75–76
 nanofibre scaffolds 276
 nanofibres 199–200, 209,
 213–14, 275–76
 nanomaterial toxicity 5, 148
 nanomaterials 4–5, 28–29, 40,
 68–69, 147–50, 177,
 201–2, 209, 211, 215–16,
 274–75, 289–91, 295,
 297–300, 310
 application of 40, 177
 unique properties of 80, 202
 nanomechanics 161–62
 nanomedicine 1–5, 7, 12–13, 15,
 17, 30, 40, 56, 68–70, 80,
 109, 123, 177–81, 190–93,
 317–18
- nanomedicine in antiretroviral
 drug development 177
 nanomedicine in atherosclerosis
 treatment 51, 53, 55
 nanomedicine in regenerative
 medicine 9, 11
 nanomedicine in vaccine
 development 179, 181
 nanomolecules 100, 162–63
 nanoparticle formulations 29, 106
 nanoparticle structure analysis
 135
 nanoparticle surface 71–72, 74
 nanoparticle systems 130, 137
 nanoparticle toxicity applications
 164
 nanoparticles 6–7, 24–27, 69–73,
 78–79, 99–101, 104–6,
 109, 129–32, 134–38,
 147–51, 160–61, 163–68,
 177–78, 190–92, 274
 cerium oxide 297, 307
 charged 149
 chemotherapeutic drugs 164
 composite 129
 copper 301
 daunorubicin 106
 fluorescent polystyrene 166
 iron 20
 metallic 294, 297, 302
 non-biodegradable 318,
 335–36
 platinum 309
 polymeric 27
 protein pDNA/PEI m 181
 silica 300–1, 334
 surfactant-free anionic PLA
 193
 nanophase ceramics 121, 209,
 217–18
 nanoscaffolds 195–202, 204, 206,
 208, 210, 212, 214, 216,
 218

- nanosensors 15, 18
 nanotechnology, applications 1, 4,
 40, 45, 177
 nanotoxicity 56, 149
 nanotoxicology 28, 161
 nanotubes 4, 8–9, 274–75, 303
 natural killer (NK) 292, 298
 natural materials 11, 197–98, 205
 nerve engineering applications
 212–13
 neural stem cells (NSCs) 213,
 244–45
 neutrophilic granulocytes (NG)
 323–24, 331–32, 334
 neutrophils 292, 300–1, 328
 NG, *see* neutrophilic granulocytes
 NK, *see* natural killer
 NSCs, *see* neural stem cells
 nuclei, carbonaceous 327–28,
 330, 332
 nutrients 166, 196, 205, 244

 odontoblasts 265, 267, 269, 271
 orthopaedic implants 121, 209,
 318–19, 321, 323, 325
 orthopaedic surgeons 116, 119,
 121, 123
 orthopaedics 115–16, 118,
 120–23
 osteoarthritis 9, 116–17, 207
 osteoblast adhesion 120, 122
 osteoblasts 122, 206–7, 209–10,
 217, 256, 325
 osteoclasts 206–7, 209, 325
 osteogenic cells 122, 260
 osteolysis 325–26
 oxidative stress 163–64, 291, 294,
 299, 303, 305, 307–8, 310

 P-selectin 42, 46, 49–50
 patients
 atherosclerotic 52–53
 relapsed 99
 PCs, *see* precursor cells
 PDL, *see* periodontal ligament
 PEGylated gold nanoparticles 73
 peptides 40, 50, 55, 72, 74, 100,
 134, 273
 periodontal ligament (PDL) 257,
 259–60, 264–65, 269
 periodontal regeneration 264,
 268–69
 periodontal tissue regeneration
 267–68
 periodontium 260, 264–66, 276
 PET, *see* positron-emission
 tomography
 phagocytosis 43, 272, 295, 298,
 325, 329, 333–34
 pharmaceutics 130
 pincushions 241–42
 placenta 149–50, 154–55, 166,
 168
 placenta barrier 149, 151,
 161–63, 166–68
 plaque disruption 40, 43–44
 plaque vulnerability 40–41, 44
 plaques 40–44, 47–49, 56
 polyethylene 320–22
 polymer pincushions 241–43
 polymeric biomaterials 229–30,
 232, 238
 polymeric scaffolds for medical
 devices 229–30, 232, 234,
 236, 238, 240, 242, 244,
 246
 polymeric scaffolds for tissue
 engineering 237
 polymers 52–53, 102, 105, 118,
 121, 197–98, 200, 202–5,
 208–10, 218, 230–31,
 234–39, 241, 243–45, 274
 biocompatibility of 233–34
 polymorphic structures 136, 138

- mixed 137
- polyplexes** 274
- polypropylene** 233
- polystyrene particles** 332, 335
- porous scaffolds** 200–1, 204
- positron-emission tomography (PET)** 19, 48–49, 57, 72, 102, 117
- precursor cells (PCs)** 270
- precursors cells** 206, 270
- pregnancy** 148–51, 166–67
- pro-inflammatory effects** 331, 333–34, 338
- progenitor cells** 263, 272, 274
- proliferation** 11–12, 42, 50, 54–55, 196, 203, 205, 208–9, 237, 244, 258, 263, 274–75, 330, 333–34
- prosthesis** 119, 320, 322
- prosthetic implants** 118–20
- protein adsorption** 121, 216, 232–33, 302
- protein adsorption on polymer surfaces** 232–33
- protein corona** 291, 302–3
- proteins** 3, 5, 11–13, 16, 18, 180, 182, 202, 206, 215–17, 229, 232–33, 236, 270, 301–3
adsorbed 232, 234
- QCM**, *see* quartz crystal microbalance
- QDs**, *see* quantum dots
- quantum dots (QDs)** 4, 6, 9, 18–20, 47, 57, 69, 103, 167, 273
- quartz crystal microbalance (QCM)** 232–33
- reactive oxygen species (ROS)** 71, 76–77, 105, 293, 295, 299, 303
- regenerative dentistry** 255–56, 258, 260, 262, 264–70, 272, 274, 276
- regenerative medicine** 1, 3–4, 9–11, 122, 196, 198, 238, 256, 276
- regulatory T-cells** 323–24
- respiratory syncytial virus (RSV)** 20, 331
- retinoic acid** 151–52
- retinoids** 150, 154–55
- RNA interference (RNAi)** 272, 274
- RNAi**, *see* RNA interference
- ROS**, *see* reactive oxygen species
- RSV**, *see* respiratory syncytial virus
- scaffold fabrication** 238–39, 241, 243
- scaffolds** 10–12, 18, 196, 198–201, 203–5, 211, 213–14, 218, 230, 237–39, 269, 272, 275
medical devices 239, 241
- Schwann cells** 213–14
- sensors** 13, 15, 19
- signalling pathways** 303–4, 310
- silica nanoparticles** 6, 300, 334
- silica particles** 332, 334
- silver nanoparticles** 165, 299–300, 308, 317, 334
- single nucleotide polymorphism (SNP)** 16
- single-photon-emission CT (SPECT)** 19, 46, 48, 58
- single-walled carbon nanotubes** 334
- SMCs**, *see* smooth muscle cells
- smooth muscle cells (SMCs)** 42–44, 49, 53, 58, 212, 246, 258
- SNP**, *see* single nucleotide polymorphism

- SPECT, *see* single-photon-emission CT
- SPR, *see* surface plasmon resonance
- stem cells 11, 107, 122, 245, 255–60, 263, 271–76
adult 256, 262
alveolar periodontal ligament 257, 260
dental mesenchymal 257
human mesenchymal 122, 272
neural 213, 244
periodontal ligament 260
transplanted 272, 276
- stents 48, 53, 55–56, 245
drug eluting 53–54, 57
- substrates, glass 241–42
- superparamagnetic iron oxide nanoparticles 71
- superparamagnetic nanoparticles 21
- surface enhanced Raman scattering (SERS) 15, 78
- surface plasmon resonance (SPR) 15, 70, 72, 232
- synthetic materials 197–98, 200, 207–8
- synthetic polymers 105, 200, 212–13, 263, 276, 291
- T-cells 175, 185–87, 190, 294, 296, 334
effector 185, 323
helper 292
memory/precursor 187
naïve 183, 185–86, 323–24, 330
precursor/memory 185, 188
- targeted drug delivery 3–5, 7, 21, 23, 25, 27, 30, 40, 56, 102
- teratoma 154–55
- theranostics 50, 69, 79
- therapeutic nanoparticles 51
- therapeutical treatment, nanoparticle-based 166
- therapeutics 23, 25, 68–70, 78, 80, 103, 289
- therapies cell-based 266–67, 272, 275–76
targeted 4, 97–100
- THR, *see* total hip replacement
- tissue adipose 256–57
bone/cartilage 122–23
cartilage 12, 122, 210
damaged 121, 202, 260, 265
dentin 266–67
diseased 18, 334
diverse 147–48
functional 214
living 9, 147–49
native 196, 212
natural 215
normal 73, 79, 100
PDL-like 259, 261
periodontal 264, 267, 269
soft 121–22, 259, 321
- tissue-derived cells 244
- tissue engineering 202–3, 205
- tissue engineering in orthopaedics 121
- tissue function 196, 213
- tissue macrophages 294, 323
- tissue regeneration 30, 196, 199, 237, 241, 265
- tissue remodelling 323, 329–30
- tissue repair 198, 237, 258, 272, 276, 332
- titania 208, 210
- titanium 118, 121, 302
- titanium dioxide 71–73, 78, 292, 335

- titanium dioxide nanoparticle regime 74–75, 79
- titanium dioxide nanoparticles 69–74, 76–77, 292, 304–7, 336
single-crystalline 76
surface of 71, 75
- TLRs, *see* toll-like receptors
- TNF, *see* tumor necrosis factor
- toll-like receptors (TLRs) 323, 326–27, 337
- tooth 257, 263–66, 268, 270, 275
- tooth eruption 256, 260, 263, 265
- tooth germs 268–69
- tooth loss 256, 264–65, 268
- tooth regeneration 256, 265, 268–71
- total hip replacement (THR) 120, 320, 322
- toxicity 21–22, 45, 48, 51, 119, 147–48, 150, 161, 164–65, 177–78, 293, 299–300, 303, 308, 310
nanoparticle-induced 293
- toxicology 29, 161, 167
- transfection efficiency 132, 135–38, 274
- treatment cadmium 159–60
retinoid analogues 151, 153
surgical 207
thalidomide 157
- treatment toxicities 94, 109
- tumor necrosis factor (TNF) 300, 324–25, 329
- tumors 4, 21, 27, 49–50, 71, 73–74, 76, 79, 93, 98–102, 117, 318, 321
- vaccines 179–80, 193
- viruses like particles (VLPs) 180, 182, 193
- vitronectin 55, 217
- VLPs, *see* viruses like particles
- wear particles 317–18, 322–27, 335, 337–38
- zinc oxide nanoparticles 292–93, 297, 299, 305
- zoledronic acid 108
liposomal 108–9